Compounds for the treatment of inflammatory disorders

1. A method of treating a condition or disease selected from the group consisting of septic shock, sepsis syndrome, post ischaemic reperfusion injury, meningitis, psoriasis, an inflammatory bowel disease, osteo and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, non-insulin dependent diabetes mellitus, asthma, and chronic obstructive pulmonary disease (COPD) in a subject comprising administering to the subject in need of such treatment a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof;

wherein the compound is represented by Formula (I):

wherein:

ring A is phenyl, which is substituted with —Y—R 1 and —Z—R 2 as shown;

X is selected from the group consisting of —S—, —O—, —S(O) 2 —, S(O)—, —(C(R 3 ) 2 ) m — and —N(R 3 )—;

T is alkynyl;

V is selected from the group consisting H, alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, and N-oxides of said heteroaryl and heterocyclyl, wherein when each of said cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, and N oxides of said heteroaryl and heterocyclyl contains two radicals on same or adjacent carbon atoms, said radicals may optionally be taken together with the carbon atom(s) to which they are attached to form a five- to eight-membered cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein each of the aforementioned cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl, optionally with said five- to eight-membered cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl is independently unsubstituted or substituted with one to four R 10 moieties which can be the same or different;

Y is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

Z is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

m is 1 to 3:

n is 1 to 3;

R 1 is selected from the group consisting of H, cyano, alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 1 alkyl, alkynyl, aryl, heteroaryl, and heterocyclyl, optionally with the five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when Y is —N(R 4 )—, —S— or —O—, then R 1 is not halogen or cyano;

R 2 is selected from the group consisting of H, cyano, alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 2 alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, optionally with five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when Z is —N(R 4 )—, —S— or —O—, then R 2 is not halogen or cyano;

each R 3 is the same of different and is independently selected from the group consisting of H, alkyl, and aryl;

each R 4 is the same or different and is independently selected from the group consisting of H, alkyl, cycloalkyl, haloalkyl, hydroxy, -alkylcycloalkyl, -alkyl-N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl;

R 10 is selected from the group consisting of hydrogen, cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 , —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, wherein each of the R 10 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl is unsubstituted or optionally independently substituted with one to four R 30 moieties which can be the same or different;

or wherein two R 10 moieties, when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 20 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 20 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 20 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cyano, nitro, —NH 2 , —NH(alkyl), and —N(alkyl) 2 ;

or when two R 20 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 30 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 30 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 30 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, nitro, —NH 2 , —NH(alkyl), and —N(alkyl) 2 ;

or when two R 30 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring.

2. The method of claim 1 , wherein the condition or disease is rheumatoid arthritis.

3. The method of claim 1 , wherein the condition or disease is inflammatory bowel disease.

4. The method of claim 3 , wherein the inflammatory bowel disease is Crohn's disease.

5. The method of claim 3 , wherein the inflammatory bowel disease is colitis.

6. The method of claim 1 , wherein the condition or disease is chronic obstructive pulmonary disorder.

7. The method of claim 1 , wherein the condition or disease is psoriasis.

8. The method of claim 1 , wherein the condition or disease is ankylosing spondylitis.

9. The method of claim 1 , wherein the condition or disease is psoriatic arthritis.

10. The method of claim 1 , wherein the compound of Formula (I) is represented by the compound of Formula (III):

wherein in Formula (III), X is —(CH 2 ) 1-2 —, and T, V, Y, R 1 , and R 3 are as set forth in claim 1 .

11. The method of claim 10 , wherein X is —CH 2 — in the compound of Formula (III).

12. The method of claim 1 , wherein the compound of Formula (I) is represented by the compound of Formula (IV):

wherein in Formula (IV), X is —(CH 2 ) 1-2 —, T, V, Z, R 2 , and R 3 are as set forth in claim 1 .

13. The method of claim 12 , wherein X is —CH 2 — in the compound of Formula (IV).

14. The method of claim 1 , wherein the compound is selected from the group of compounds set forth below:

15. The method of claim 14 , wherein the condition or disease is rheumatoid arthritis.

16. The method of claim 14 , wherein the condition or disease is inflammatory bowel disease.

17. The method of claim 16 , wherein the inflammatory bowel disease is Crohn's disease.

18. The method of claim 16 , wherein the inflammatory bowel disease is colitis.

19. The method of claim 14 , wherein the condition or disease is chronic obstructive pulmonary disorder.

20. The method of claim 14 , wherein the condition or disease is psoriasis.

21. The method of claim 14 , wherein the condition or disease is ankylosing spondylitis.

22. The method of claim 14 , wherein the condition or disease is psoriatic arthritis.

23. The method of claim 1 , wherein the compound is selected from the group of compounds set forth below:

24. The method of claim 23 , wherein the condition or disease is rheumatoid arthritis.

25. The method of claim 23 , wherein the condition or disease is inflammatory bowel disease.

26. The method of claim 16 , wherein the inflammatory bowel disease is Crohn's disease.

27. The method of claim 16 , wherein the inflammatory bowel disease is colitis.

28. The method of claim 23 , wherein the condition or disease is chronic obstructive pulmonary disorder.

29. The method of claim 23 , wherein the condition or disease is psoriasis.

30. The method of claim 23 , wherein the condition or disease is ankylosing spondylitis.

31. The method of claim 23 , wherein the condition or disease is psoriatic arthritis.